M. Pal et al. / Tetrahedron Letters 47 (2006) 3923–3928
3927
3
. Gomtsyan, A.; Didomenico, S.; Lee, C.-H.; Matulenko,
M. A.; Kim, K.; Kowaluk, E. A.; Wismer, C. T.; Mikusa,
J.; Yu, H.; Kohlhaas, K.; Jarvis, M. F.; Bhagwat, S. S. J.
Med. Chem. 2002, 45, 3639.
. (a) Spector, T.; Porter, D. J. T.; Nelson, D. J.; Baccanari,
D. P.; Davis, S. T.; Almond, M. R.; Khor, S. P.; Amyx,
H.; Cao, S.; Rustum, Y. M. Drugs Fut. 1994, 19, 565; (b)
Kundu, N. G.; Das, B.; Spears, C. P.; Majumdar, A.;
Kang, S. I. J. Med. Chem. 1990, 33, 1975.
. Norman, M. H.; Chen, N.; Chen, Z.; Fotsch, C.; Hale, C.;
Han, N.; Hurt, R.; Jenkins, T.; Kincaid, J.; Liu, L.; Lu,
Y.; Moreno, O.; Santora, V. J.; Sonnenberg, J. D.;
Karbon, W. J. Med. Chem. 2000, 43, 4288.
1995, 60, 1408; (l) Mangalagiu, I.; Benneche, T.; Undheim,
K. Acta Chem. Scand. 1996, 50, 914; (m) Ple, N.; Turck,
A.; Heynderickx, A.; Queguiner, G. J. Heterocycl. Chem.
1997, 34, 551; (n) Chambers, R. D.; Hall, C. W.;
Hutchinson, J.; Millar, R. W. J. Chem. Soc., Perkin
Trans. 1 1998, 1705; (o) Kim, C.-S.; Russell, K. C. J. Org.
Chem. 1998, 63, 8229; (p) Djung, J. F.; Hart, D. J.; Young,
E. R. R. J. Org. Chem. 2000, 65, 5668; (q) Molander, G.
A.; Katona, B. W.; Machrouhi, F. J. Org. Chem. 2002, 67,
8416; (r) Kim, J. T.; Gevorgyan, V. Org. Lett. 2002, 4,
4697; (s) Susvilo, I.; Brukstus, A.; Tumkevicius, S. Synlett
2003, 1151; For a review, see: (t) Schr o¨ ter, S.; Stock, C.;
Bach, T. Tetrahedron 2005, 61, 2245.
4
5
6
. Djung, J. F.; Hart, D. J.; Young, E. R. R. J. Org. Chem.
13. For the use of 5-bromo-4-chloropyrimidines in other Pd-
catalyzed reactions, see: (a) Sandosham, J.; Undheim, K.
Acta Chem. Scand. 1989, 43, 62; See also: (b) Kuo, G.-H.;
Wang, A.; Emanuel, S.; DeAngelis, A.; Zhang, R.;
Connolly, P. J.; Murray, W. V.; Gruninger, R. H.;
Sechler, J.; Fuentes-Pesquera, A.; Johnson, D.; Middle-
ton, S. A.; Jolliffe, L.; Chen, X. J. Med. Chem. 2005, 48,
1886–1900; (c) Sonogashira, K.; Tohda, Y.; Hagihara, N.
Tetrahedron Lett. 1975, 16, 4467; For a review, see: (d) de
Meijere, A.; Meyer, F. E. Angew. Chem., Int. Ed. Engl.
1994, 33, 2379.
2
000, 65, 5668.
7
. Timmer, R. T.; Alexander, C. W.; Pillarisetti, S.; Saxena,
U.; Yeleswarapu, K. R.; Pal, M.; Reddy, J. T.; Reddy, V.
V. R. M. K.; Sridevi, B. S.; Kumar, P. R.; Reddy, G. O.
World Patent Application WO 2004026844 A1, April 1,
2
004; Chem. Abstr. 2004, 140, 303704.
8
. (a) Padakanti, S.; Veeramaneni, V. R.; Pattabiraman, V.
R.; Pal, M.; Yeleswarapu, K. R. Tetrahedron Lett. 2002,
4
3, 8715; (b) Pattabiraman, V. R.; Padakanti, P. S.;
Veeramaneni, V. R.; Pal, M.; Yeleswarapu, K. R. Synlett
002, 947; (c) Pal, M.; Swamy, N. K.; Hameed, P. S.;
Padakanti, S.; Yeleswarapu, K. R. Tetrahedron 2004, 60,
987; (d) Pal, M.; Veeramaneni, V. R.; Nagaballi, M.;
2
14. (a) Batchu, V. R.; Subramanian, V.; Parasuraman, K.;
Swamy, N. K.; Kumar, S.; Pal, M. Tetrehedron 2005, 61,
9869; (b) Novak, Z.; Szabo, A.; Repasi, J.; Kotschy, A. J.
3
Kalleda, S. R.; Misra, P.; Casturi, S. R.; Yeleswarapu, K.
R. Bioorg. Med. Chem. Lett. 2003, 13, 1639; (e) Pal, M.;
Madan, M.; Srinivas, P.; Pattabiraman, V. R.; Kalleda, S.
R.; Akhila, V.; Ramesh, M.; Rao Mamidi, N. V. S.;
Casturi, S. R.; Malde, A.; Gopalakrishnan, B.; Yeleswa-
rapu, K. R. J. Med. Chem. 2003, 46, 3975; (f) Pal, M.;
Veeramaneni, V. R.; Kumar, S.; Vangoori, A.; Mullangi,
R.; Misra, P.; Rajjak, S. A.; Lohray, V. B.; Casturi, S. R.;
Yeleswarapu, K. R. Lett. Drug Des. Disc. 2005, 2, 329.
. (a) Pal, M.; Batchu, V. R.; Khanna, S.; Yeleswarapu, K.
R. Tetrahedron 2002, 58, 9933; (b) Pal, M.; Batchu, V. R.;
Parasuraman, K.; Yeleswarapu, K. R. J. Org. Chem. 2003,
2
Org. Chem. 2003, 68, 3327; For the use of Pd(OH) /C as
catalyst, see: (c) Mori, Y.; Seki, M. J. Org. Chem. 2003, 68,
1571; (d) Heidenreich, R. G.; K o¨ hler, K.; Krauter, J. G.
E.; Pietsch, J. Synlett 2002, 1118; (e) Felpin, F.-X.; Vo-
Thanh, G.; Villie’ras, J.; Lebreton, J. Tetrahedron: Asym-
metry 2001, 12, 1121; (f) Bates, R. W.; Boonsombat, J. J.
Chem. Soc., Perkin Trans. 1 2001, 654; (g) Bleicher, L. S.;
Cosford, N. D. P.; Herbaut, A.; McCallum, J. S.;
McDonald, I. A. J. Org. Chem. 1998, 63, 1109; (h)
Bleicher, L.; Cosford, N. D. P. Synlett 1995, 1115; (i)
Potts, K. T.; Horwitz, C. P.; Fessak, A.; Keshavarz, K.
M.; Nash, K. E.; Toscano, P. J. J. Am. Chem. Soc. 1993,
115, 10444; (j) De la Rosa, M. A.; Velarde, E.; Guzman,
A. Synth. Commun. 1990, 20, 2059.
9
6
8, 6806; (c) Pal, M.; Dakarapu, R.; Padakanti, S. J. Org.
Chem. 2004, 69, 2913; (d) Pal, M.; Batchu, V. R.; Dager,
I.; Swamy, N. K.; Padakanti, S. J. Org. Chem. 2005, 70,
15. (a) Pal, M.; Dakarapu, R.; Parasuraman, K.; Subrama-
nian, V.; Yeleswarapu, K. R. J. Org. Chem. 2005, 70,
7179; (b) Subramanian, V.; Batchu, V. R.; Barange, D.;
Pal, M. J. Org. Chem. 2005, 70, 4778; (c) Pal, M.;
Parasuraman, K.; Yeleswarapu, K. R. Org. Lett. 2003, 5,
349; (d) Pal, M.; Parasuraman, K.; Gupta, S.; Yeleswa-
rapu, K. R. Synlett 2002, 1976; (e) Pal, M.; Subramanian,
V.; Yeleswarapu, K. R. Tetrahedron Lett. 2003, 44, 8221;
For Pd-catalyzed alkynylation of a pyrimidine ring, see: (f)
Pal, M.; Kundu, N. G. J. Chem. Soc., Perkin Trans. 1
1996, 449; (g) Raju, S.; Batchu, V. R.; Swamy, N. K.; Dev,
R. V.; Babu, J. M.; Kumar, P. R.; Mukkanti, K.; Pal, M.
Tetrahedron Lett. 2006, 47, 83.
2
376.
1
1
1
0. The enediynes are a class of antitumour agents with
spectacular biological profiles and proven clinical efficacy,
see: (a) Smith, A. L.; Nicolaou, K. C. J. Med. Chem. 1996,
3
9, 2103; (b) Nicolaou, N. C.; Dai, W. M.; Tsay, S. C.;
Estevez, V. A.; Wrasidlo, W. Science 1992, 256, 1172.
1. (a) Adamo, M. F. A.; Adlington, R. M.; Baldwin, J. E.;
Pritchard, G. J.; Rathmell, R. E. Tetrahedron 2003, 59,
2
197; (b) Baldwin, J. E.; Pritchard, G. J.; Rathmell, R. E.
J. Chem. Soc., Perkin Trans. 1 2001, 2906; (c) d’Alarcao,
M.; Leonard, N. J. J. Am. Chem. Soc. 1983, 105, 5958.
2. (a) Edo, K.; Yamanaka, H.; Sakamoto, T. Heterocycles
1
978, 9, 271; (b) Edo, K.; Sakamoto, T.; Yamanaka, H.
16. Compound Ia was prepared by brominating 2-amino-6-
methyl-3H-pyrimidin-4-one with bromine in acetic acid
Chem. Pharm. Bull. 1978, 26, 3843; (c) Kato, T.; Sato, M.;
Wagai, A. J. Heterocycl. Chem. 1979, 16, 1575; (d)
Sakamoto, T.; Tanji, K.-i.; Shiraiwa, M.; Arakida, H.;
Kondo, Y.; Yamanaka, H. Heterocycles 1982, 19, 184; (e)
Tanji, K.-I.; Sakamoto, T.; Yamanaka, H. Chem. Pharm.
Bull. 1982, 30, 1865; (f) Sakamoto, T.; Kondo, Y.;
Yamanaka, H. Chem. Pharm. Bull. 1982, 30, 2410; (g)
Sakamoto, T.; Shiraiwa, M.; Kondo, Y.; Yamanaka, H.
Synthesis 1983, 312; (h) Solberg, J.; Undheim, K. Acta
Chem. Scand. Ser. B 1986, 40, 381; (i) Sakamoto, T.;
Shiga, F.; Yasuhara, A.; Uchiyama, D.; Kondo, Y.;
Yamanaka, H. Synthesis 1992, 8, 746; (j) Brakta, M.;
Daves, G. D. J. Chem. Soc., Perkin Trans. 1 1992, 1883;
3
followed by the treatment with POCl according to a
procedure described in the literature, see for example: (a)
Price, C. C.; Leonard, N. J.; Reitsema, R. H. J. Am. Chem.
Soc. 1946, 68, 766; (For the preparation 2-amino-6-
methyl-3H-pyrimidin-4-one, see: Jaeger, R. Justus Liebigs
Ann. Chem. 1891, 262, 365); Compound Ib was prepared
by reacting 6-methyl-2-thioxo-2,3-dihydro-1H-pyrimidin-
4-one with bromoethane in the presence of NaH in DMF
at 80 ꢁC for 16 h. The resulting 2-ethylsulfanyl-6-methyl-
3H-pyrimidin-4-one was brominated in acetic acid (see: (b)
Erkin, A. V.; Krutikov, V. I.; Pavlovich, N. I. Russ. J.
Gen. Chem. 2003, 73, 463) and then treated with POCl
according to a similar procedure described in the litera-
3
(
k) Boucher, E.; Simard, M.; Wuest, J. D. J. Org. Chem.